H.C. Wainwright raised the firm’s price target on Relay Therapeutics to $20 from $17 and keeps a Buy rating on the shares following the Q4 report. The firm sees milestones within the next six to 12 months, including potential disclosures from Roche regarding the clinical development of RLY-1971.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on RLAY:
- Relay Therapeutics reports Q 4 EPS (67c), consensus (75c)
- Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
- Relay Therapeutics price target raised to $30 from $25 at Stifel
- Relay Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights on February 22, 2024
- Relay Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
